U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Meta Expands AI Training With Employee Activity Tracking Tools 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
FORT WASHINGTON, Pa., Feb. 25, 2016 -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, will host a conference call on Thursday, March 3, 2016 at 4:30 p.m. EST to discuss fourth quarter and full year 2015 financial results and recent operational highlights. A question-and-answer session will follow Vitae's remarks.
To participate on the live call, please dial 844-423-9893 (domestic) or +1-716-247-5808 (international) and provide the conference ID 57209176 five to 10 minutes before the start of the call.
A live audio webcast of the call will also be available via the "Investor Relations" page of the Vitae website, www.vitaepharma.com. Please log on through Vitae's website approximately 10 minutes before the scheduled start time. A replay of the webcast will be archived on Vitae's website for 90 days following the call.
About Vitae Pharmaceuticals
Vitae Pharmaceuticals is a clinical-stage biotechnology company developing first-in-class product candidates with potential to transform the treatment paradigm for patients with significant unmet medical needs. Initial indications being pursued include psoriasis, other autoimmune disorders, and atopic dermatitis. Vitae’s lead clinical assets include VTP-43742, an oral RORgt inhibitor currently being studied in patients with moderate to severe psoriasis, and VTP-38543, an LXRβ selective agonist being studied in patients with mild to moderate atopic dermatitis.
For additional information, please visit the company's website at www.vitaepharma.com.
INVESTORS: Vitae Pharmaceuticals, Inc. Richard S. Morris, CPA Chief Financial Officer (215) 461-2000 [email protected] Westwicke Partners John Woolford (443) 213-0506 [email protected] MEDIA: 6 Degrees PR Tony Plohoros (908) 591-2839 [email protected]
